News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck KGaA (MKGAF.PK) Pulls Plug on Cladribine on FDA Feedback


6/22/2011 6:47:55 AM

Merck KGaA said U.S. drug regulators' concerns about the risks of its cladribine pill will put an end to any development or marketing plans for the multiple sclerosis (MS) treatment. Merck also said on Wednesday it planned to withdraw cladribine from markets in Australia and Russia where it has been approved and is available under the name Movectro. Its shares were down 1.8 percent, underperforming a 0.5 percent lower European healthcare sector index . "Merck believes that data from ongoing clinical trials are very unlikely to address the (U.S. Food and Drug Administration's) requirements," it said, adding new trials would not justify the costs.

Read at Reuters
Read at RTT News
Read at Bloomberg
Read at Nasdaq

comments powered by Disqus
Reuters
RTT News
Bloomberg
Nasdaq
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES